ADVERTISEMENT
Adam D. Cohen, MD, Discusses Therapy Options for Multiple Myeloma
Adam D. Cohen, MD, Director, Myeloma Immunotherapy, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, shares his thoughts on several abstracts presented at the 2018 ASH Annual Meeting that pertained to therapy options for multiple myeloma.
Listen to the entire 3-part podcast series below.
---
Earlier Daratumamab Use Feasible for Relapsed/ Refractory Multiple Myeloma
Dr Cohen shares data from several studies that explored the use of daratumamab earlier in multiple myeloma treatment.
Novel Immunotherapy Approaches for Multiple Myeloma
Dr Cohen discusses a few promising immunotherapy approaches for patients with multiple myeloma.
Ixazomib Promising Maintenance Therapy Option for Multiple Myeloma
Dr Cohen shares data from a study looking at ixazomib as a maintenance therapy option for patients with multiple myeloma.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Visit the OLN Excellence Forums
Advertisement
Advertisement
Advertisement